9 Best Mersana Therapeutics Alternatives & Competitors (2026)

Enhertu is AstraZeneca and Daiichi Sankyo's approved HER2-directed ADC used across multiple solid tumours. It offers strong clinical efficacy and a cleavable linker but relies on single-antigen targeting without logic gating. Compared with Valink Therapeutics, Enhertu has far greater clinical validation and commercial scale while Valink's V-Gate bispecific design seeks improved selectivity and resistance overcoming in earlier discovery stages.

Trodelvy is Gilead's TROP-2 directed ADC approved for breast and urothelial cancers. It uses a moderately toxic payload and standard targeting. Versus Valink, Trodelvy provides real-world use data and broader indications today, whereas Valink's dual-target V-Gate approach aims for tighter tumour restriction and new payload opportunities not yet clinically tested.

Adcetris (brentuximab vedotin) from Seagen/Pfizer was one of the first approved ADCs targeting CD30 in lymphomas. It demonstrates durable responses but faces resistance issues common to single-target ADCs. Valink Therapeutics positions its bispecific V-Gate candidates as potential solutions for similar resistance mechanisms through multi-antigen logic in solid tumours where Adcetris is not indicated.

Polivy is Roche's CD79b-targeted ADC approved for diffuse large B-cell lymphoma in combination regimens. It shows strong activity in hematologic malignancies. Valink focuses on solid tumour programs with continuous-level gating technology that Polivy lacks, targeting different biology and tissue distribution challenges.

GSK's Blenrep is a BCMA-directed ADC for multiple myeloma that was later withdrawn in some markets due to safety concerns. Its experience highlights the need for improved selectivity. Valink's V-Gate platform is designed to enhance tumour-versus-healthy discrimination, potentially mitigating similar toxicity risks in future ADCs.

Sutro uses cell-free expression to create homogeneous ADCs and bispecifics with precise conjugation. Their pipeline includes several oncology candidates. Valink similarly pursues bispecific ADCs but adds continuous-level gating and an integrated AI screening platform that Sutro's technology does not explicitly feature.

ImmunoGen specialises in ADCs with maytansinoid and IGN payloads and has an approved product in ovarian cancer. Its focus remains largely single-antigen. Valink differentiates by developing dual-target V-Gate molecules intended to expand the addressable patient population beyond what ImmunoGen's current portfolio targets.

Zymeworks develops multifunctional biotherapeutics including bispecific ADCs via its Azymetric and ZymeLink platforms. It has partnerships and clinical programs. Relative to Valink, Zymeworks offers more advanced clinical-stage bispecific assets while Valink emphasises AI-driven exploration of continuous-level gating logic for solid tumours.